Susquehanna International Group
OKUR

Susquehanna International Group’s OnKure Therapeutics OKUR Stock Holding History

Susquehanna International Group’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-14,200
Closed -$122K – 13678
2024
Q4 		$122K Buy
14,200
+9,120
+180% +$138K ﹤0.01% 11179
2024
Q3 		$86.4K Sell
5,080
-90
-2% -$1.33K ﹤0.01% 11138
2024
Q2 		$78.1K Sell
5,170
-6,930
-57% -$117K ﹤0.01% 11186
2024
Q1 		$201K Buy
12,100
+8,340
+222% +$138K ﹤0.01% 10590
2023
Q4 		$60.2K Buy
+3,760
New +$234K ﹤0.01% 11639

Other funds holding OKUR

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Susquehanna International Group's OKUR Position: Q3 2024 in Review

Susquehanna International Group sold out of OnKure Therapeutics (OKUR) in Q3 2024, closing a stake of 6,962 shares — an estimated $103K sold.

Susquehanna International Group first reported a position in OKUR in Q3 2022 and held it in 5 quarters. The position peaked at $194K in Q1 2023. 51 funds tracked by Wall St. Rank hold OKUR as of Q3 2024.

  • Susquehanna International Group reported no remaining OnKure Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Susquehanna International Group sold 6,962 OnKure Therapeutics shares in Q3 2024, an estimated $103K.
  • Susquehanna International Group first reported a position in OnKure Therapeutics in Q3 2022 and held it in 5 quarters.
  • Susquehanna International Group's OnKure Therapeutics position peaked at $194K in Q1 2023.
  • 51 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q3 2024.

Based on Susquehanna International Group's 13F filing for Q3 2024, filed 14 Nov 2024.